Janumet and Rocephin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Janumet (metformin hydrochloride; sitagliptin phosphate) and Rocephin (ceftriaxone sodium). Common drug interactions include abdominal pain upper among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Janumet and Rocephin. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Janumet?

Janumet has active ingredients of metformin hydrochloride; sitagliptin phosphate. It is often used in diabetes. eHealthMe is studying from 25,023 Janumet users. Check the latest studies of Janumet.

What is Rocephin?

Rocephin has active ingredients of ceftriaxone sodium. It is often used in infection. eHealthMe is studying from 15,665 Rocephin users. Check the latest studies of Rocephin.



On Jul, 26, 2026

12 people who take Janumet and Rocephin together, and have interactions are studied.

Janumet and Rocephin drug interactions.

What are the common drug interactions of Janumet and Rocephin, by gender? *:

female:

  1. Abdominal pain upper
  2. Fall
  3. Hepatic enzyme increased
  4. Hepatic steatosis (fatty liver disease)
  5. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
  6. Pancreatitis (inflammation of pancreas)
  7. Post procedural haematoma (post procedural clotting of blood)
  8. Pruritus (severe itching of the skin)
  9. Rash
  10. Vascular pseudoaneurysm (leakage of arterial blood from an artery into the surrounding tissue with a continuing communication between the originating artery and the resultant adjacent cavity)

male:

  1. Abdominal pain
  2. Aphasia (damage to the parts of the brain that control language)
  3. Ulcer
  4. Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
  5. Cardiac failure
  6. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  7. Fungal infection
  8. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  9. Pharyngitis streptococcal (inflammation of the pharynx caused by infection from. streptococcus)
  10. Renal disorder (kidney disease)

What are the common drug interactions of Janumet and Rocephin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  2. Pharyngitis streptococcal (inflammation of the pharynx caused by infection from. streptococcus)
  3. Renal disorder (kidney disease)

50-59:

  1. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  2. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)

60+:

  1. Hepatic enzyme increased
  2. Abdominal pain
  3. Pancreatitis (inflammation of pancreas)
  4. Post procedural haematoma (post procedural clotting of blood)
  5. Pruritus (severe itching of the skin)
  6. Rash
  7. Vascular pseudoaneurysm (leakage of arterial blood from an artery into the surrounding tissue with a continuing communication between the originating artery and the resultant adjacent cavity)
  8. Anaemia (lack of blood)
  9. Drug hypersensitivity
  10. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)

What are the existing conditions these people have? *

  1. Type 2 Diabetes: 5 people, 41.67%
  2. Pain: 3 people, 25.00%
  3. Dyspnea (difficult or laboured breathing): 3 people, 25.00%
  4. High Blood Pressure: 3 people, 25.00%
  5. Hypersensitivity: 2 people, 16.67%
  6. Abdominal Pain Upper: 2 people, 16.67%
  7. Anaesthesia: 2 people, 16.67%
  8. Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 16.67%
  9. Nausea (feeling of having an urge to vomit): 2 people, 16.67%
  10. Abdominal Pain: 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Janumet and Rocephin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Janumet and Rocephin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Janumet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rocephin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Janumet and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rocephin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on metformin hydrochloride; sitagliptin phosphate and ceftriaxone sodium (the active ingredients of Janumet and Rocephin, respectively), and Janumet and Rocephin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: